A Novel Pre-treatment Approach to Ulcerative Colitis in a Mouse Model

Background: Inflammatory Bowel Disease (IBD) is a complex multifactorial disease that includes two Crohn's disease and ulcerative colitis (UC). The UC characterized by inflammation, oxidative stress, and increased intestinal epithelial cell apoptosis. The present study aiming to investigate the...

Full description

Saved in:
Bibliographic Details
Published in:Iranian journal of colorectal research Vol. 10; no. 4; pp. 150 - 159
Main Authors: Vahid Pouresmaeil, Amir Hooshang Mohammadpour, Vahid Ariabod, Atena Pourtaji
Format: Journal Article
Language:English
Published: Shiraz University of Medical Sciences 01-12-2022
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Background: Inflammatory Bowel Disease (IBD) is a complex multifactorial disease that includes two Crohn's disease and ulcerative colitis (UC). The UC characterized by inflammation, oxidative stress, and increased intestinal epithelial cell apoptosis. The present study aiming to investigate the protective potential of a combination of five safety products: Bromelain (BR), Silibinin (SB), Alpha-lipoic acid (ALA), Inulin (IN) and Sodium butyrate (BU) against UC. Methods: Seventy-two male Balb/c mice were divided into 9 groups, and administered for 14 days by a minimum effective dose of BR, SB, ALA, IN, BU or all together (PAC). Mesalazine (MZ) is used to compare the therapeutic effects of the compounds. Colitis was induced by rectal injection of acetic acid (4%) in 12th day. Blood and colon tissue were collected and the expression of inflammatory cytokines, and oxidative stress indices were examined using ELISA methods. The SPSS v.24 was used for data analysis.Results: All the therapeutic groups including BR, IN, BU, ALA, SB separately, partially improved histopathological changes due to colitis, but PAC treatment prior to colitis induction significantly (p<0.001), and more effectively alleviated the extent and intensity of the histological signs of cell damage including inflammation intensity, macroscopic and microscopic colon damage, and improved colitis. A significant decrease in inflammatory cytokines and oxidative stress indices also observed in the group treated with ALA, SB and PAC.Conclusion: This new drug combination (PAC) is more beneficial for the prevention of UC better than MZ that is a usual treatment of UC.
AbstractList Background: Inflammatory Bowel Disease (IBD) is a complex multifactorial disease that includes two Crohn's disease and ulcerative colitis (UC). The UC characterized by inflammation, oxidative stress, and increased intestinal epithelial cell apoptosis. The present study aiming to investigate the protective potential of a combination of five safety products: Bromelain (BR), Silibinin (SB), Alpha-lipoic acid (ALA), Inulin (IN) and Sodium butyrate (BU) against UC. Methods: Seventy-two male Balb/c mice were divided into 9 groups, and administered for 14 days by a minimum effective dose of BR, SB, ALA, IN, BU or all together (PAC). Mesalazine (MZ) is used to compare the therapeutic effects of the compounds. Colitis was induced by rectal injection of acetic acid (4%) in 12th day. Blood and colon tissue were collected and the expression of inflammatory cytokines, and oxidative stress indices were examined using ELISA methods. The SPSS v.24 was used for data analysis.Results: All the therapeutic groups including BR, IN, BU, ALA, SB separately, partially improved histopathological changes due to colitis, but PAC treatment prior to colitis induction significantly (p<0.001), and more effectively alleviated the extent and intensity of the histological signs of cell damage including inflammation intensity, macroscopic and microscopic colon damage, and improved colitis. A significant decrease in inflammatory cytokines and oxidative stress indices also observed in the group treated with ALA, SB and PAC.Conclusion: This new drug combination (PAC) is more beneficial for the prevention of UC better than MZ that is a usual treatment of UC.
Author Vahid Pouresmaeil
Atena Pourtaji
Amir Hooshang Mohammadpour
Vahid Ariabod
Author_xml – sequence: 1
  fullname: Vahid Pouresmaeil
  organization: Department of Biochemistry, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran
– sequence: 2
  fullname: Amir Hooshang Mohammadpour
  organization: Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
– sequence: 3
  fullname: Vahid Ariabod
  organization: Department of Pathology, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran
– sequence: 4
  fullname: Atena Pourtaji
  organization: Pharmaceutical Research Center, Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
BookMark eNqtjEFKAzEUQIMoWLVHEHKBGZOfTJMuS6noQnGh6_Cb_mpKOhl-YsHbK-IR3LwHb_GuxPlYRhLiVqveKOsWdxiZe1Bg-qUbNPRaL-yZmIHzpgNr1KWY13pQSoF3Bryfic1KPpcTZfnC1DUmbEcam1xNExeMH7IV-ZYjMbZ0IrkuObVUZRolyqfyWemHO8o34mKPudL8z9fi8X7zun7odgUPYeJ0RP4KBVP4DYXfA3JLMVNYDoh7FdGD3VqjvVdxQLN13kcNAGT-8_UNR2dcEw
ContentType Journal Article
DBID DOA
DOI 10.30476/acrr.2023.97512.1164
DatabaseName Directory of Open Access Journals
DatabaseTitleList
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2783-2430
EndPage 159
ExternalDocumentID oai_doaj_org_article_95aaf0ca824b431880c5a3b788c1222e
GroupedDBID ABDBF
AFWDF
ALMA_UNASSIGNED_HOLDINGS
GROUPED_DOAJ
M~E
ID FETCH-doaj_primary_oai_doaj_org_article_95aaf0ca824b431880c5a3b788c1222e3
IEDL.DBID DOA
IngestDate Tue Oct 22 15:09:35 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 4
Language English
LinkModel DirectLink
MergedId FETCHMERGED-doaj_primary_oai_doaj_org_article_95aaf0ca824b431880c5a3b788c1222e3
OpenAccessLink https://doaj.org/article/95aaf0ca824b431880c5a3b788c1222e
ParticipantIDs doaj_primary_oai_doaj_org_article_95aaf0ca824b431880c5a3b788c1222e
PublicationCentury 2000
PublicationDate 2022-12-01
PublicationDateYYYYMMDD 2022-12-01
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-01
  day: 01
PublicationDecade 2020
PublicationTitle Iranian journal of colorectal research
PublicationYear 2022
Publisher Shiraz University of Medical Sciences
Publisher_xml – name: Shiraz University of Medical Sciences
SSID ssj0002873288
Score 4.5101748
Snippet Background: Inflammatory Bowel Disease (IBD) is a complex multifactorial disease that includes two Crohn's disease and ulcerative colitis (UC). The UC...
SourceID doaj
SourceType Open Website
StartPage 150
SubjectTerms inflammatory cytokines
oxidative stress
preventive drug
ulcerative colitis
Title A Novel Pre-treatment Approach to Ulcerative Colitis in a Mouse Model
URI https://doaj.org/article/95aaf0ca824b431880c5a3b788c1222e
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ07T8MwEMdP0AGxIJ7irRtYQxPHeXgMJVUZWiEBElvkOBcJFCUobfn8-BFVMDHA6sE-nR_nv33-GeAmkgmPQhF4SSBTj1NlplSderFfVor7xAJL4Js9JYvX9D43mJzNV18mJ8zhgZ3jxiKSsvaVTBkvdbDTw01FMiy1clOBjm1kV18__iam3u2RkYHQpO7JjrlZisdS9Yb_ycJbkegop9eKmP8A9duIMt2HvWEriJkz4QC2qD2Enflw2X0EeYaL7pMafOzJ2ySEYzZQwHHV4UujyKG7cWIT2Zb41qLEudbzhOafs-YYHqb582TmGROKDweXKAzu2RZoJxSDE4rfnBCewKjtWjoFLLU-q7WGKEvdCxSQ4MQSX1AsRMUo4mdw9_f2zv-jkgvYZeYtgc0NuYTRql_TFWwvq_W17cwv_pmmLQ
link.rule.ids 315,782,786,866,2106,27933,27934
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Novel+Pre-treatment+Approach+to+Ulcerative+Colitis+in+a+Mouse+Model&rft.jtitle=Iranian+journal+of+colorectal+research&rft.au=Vahid+Pouresmaeil&rft.au=Amir+Hooshang+Mohammadpour&rft.au=Vahid+Ariabod&rft.au=Atena+Pourtaji&rft.date=2022-12-01&rft.pub=Shiraz+University+of+Medical+Sciences&rft.eissn=2783-2430&rft.volume=10&rft.issue=4&rft.spage=150&rft.epage=159&rft_id=info:doi/10.30476%2Facrr.2023.97512.1164&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_95aaf0ca824b431880c5a3b788c1222e